Osteopontin (OPN) improves risk stratification in pulmonary hypertension (PH)

International Journal of Cardiology

Volumn 155, Issue 3, 2012, Pages 504-505

  Rosenberg, Mark ^a   Meyer, F Joachim ^b   Gruenig, Ekkehard ^c   Schuster, Tibor ^d   Lutz, Matthias ^a   Lossnitzer, Dirk ^e   Wipplinger, Rita ^e   Katus, Hugo A ^e   Frey, Norbert ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Klinikum Harlaching   (Germany)

^c Thoraxklinik Heidelberg   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarker; Osteopontin; Prognosis; Pulmonary hypertension

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; OSTEOPONTIN;

6 MINUTE WALK TEST; ADULT; CAUSE OF DEATH; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HEART FAILURE; HEART RIGHT ATRIUM PRESSURE; HUMAN; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; INTEGRATED DISCRIMINATION IMPROVEMENT ANALYSIS; LETTER; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RISK ASSESSMENT; SCLERODERMA; SENSITIVITY AND SPECIFICITY;

EID: 84857781686     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.12.108     Document Type: Article

References (15)

1. M. Rosenberg, C. Zugck, and M. Nelles Osteopontin, a new prognostic biomarker in patients with chronic heart failure Circ Heart Fail 1 2008 May 43 49
2. H. Okamoto Osteopontin and the cardiovascular system Mol Cell Biochem 300 2007 1 7
3. K. Singh, G. Sirokman, and C. Communal Myocaridal Osteopontin Expression Coincides With the Development of Heart Failure Hypertension 33 1999 663 670 (Pubitemid 29091644)
4. M.J. Pecina, S.R. D́Agostino RB, J.R. D́Agostino RB, and R.S. Vasan Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 (Pubitemid 351193639)
5. Y.F. Chen, J.A. Feng, and P. Li Dominant negative mutation of the TGF- receptor block pulmonary vascular remodeling J Appl Physiol 100 2006 564 571 (Pubitemid 43671609)
6. D.L. Burke, M.G. Frid, and C.L. Kunrath Sustained hypoxia promotes the development of a chronic inflammatory microenvironment Am J Physiol Lung Cell Mol Physiol 297 2009 L238 L250
7. L. Liaw, M.P. Skinner, and E.W. Raines The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro J Clin Invest 95 1995 713 724
8. L. Liaw, V. Lindner, S.M. Schwartz, A.F. Chambers, and C.M. Giachelli Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro Circ Res 77 1995 665 672
9. E.R. O'Brien, M.R. Garvin, and D.K. Stewart Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques Arterioscler Thromb 14 1994 1648 1656
10. L. Liaw, M. Almeida, C.E. Hart, S.M. Schwartz, and C.M. Giachelli Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro Circ Res 74 1994 214 224 (Pubitemid 24029153)
11. K. Isoda, K. Nishikawa, and Y. Kamezawa Osteopontin plays an important role in the development of medial thickening and neointimal formation Circ Res 91 2002 77 82 (Pubitemid 34778945)
12. K.N. Cowan, P.L. Jones, and M. Rabinovitch Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease J Clin Invest 105 2000 21 34 (Pubitemid 30036384)
13. Z. Xie, M. Singh, and K. Singh Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice Hypertension 44 2004 826 831 (Pubitemid 39577407)
14. S. Schaefer, P. Ellinghaus, and W. Janssen Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodeling Cardiovasc Res 82 2009 30 39
15. V.K. Munagala, J.C. Burnett Jr. , and M.M. Redfield The natriuretic peptides in cardiovascular medicine Curr Probl Cardiol 29 2004 707 769 (Pubitemid 39488317)